Prognostic Factors of Radiofrequency Ablation plus Systemic Chemotherapy for Unresectable Colorectal Cancer with Liver Metastasis

Doan, Ky Thai; Việt, Long Nguyễn; Tien, Thinh Nguyen; Canh, Binh Nguyen; Thi, Hoai Ngo; Thanh, Ngoc Nguyen; Quang, Bieu Bui; Van, Quang Le; Lee, Hyun Woong; Mai, Bang Hong

doi:10.1155/2020/8836922

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other favorable prognostic factors were 25-hydroxyvitamin D > 20 ng/mL [ 23 ] and lymphocyte-to-monocyte ratio > 3.96% [ 21 ]. Several studies have demonstrated a larger number of liver metastasis [ 10 , 15 , 16 , 26 ] and the presence of extrahepatic metastases [ 10 , 15 , 18 , 20 , 22 , 26 ] to be associated with a significantly shorter OS. The other reported negative prognostic factors were Kras mutation [ 20 ], BRAF mutation [ 11 ], intrahepatic recurrence [ 10 ], LTP at the 6-month follow-up [ 17 ], high tumor grade [ 11 ], distant metastasis at diagnosis of the primary tumor [ 11 ], and previous radiation therapy [ 11 ].…”

Section: Results In Each Type Of Primary Tumormentioning

confidence: 99%

Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade

et al. 2022

View full text Add to dashboard Cite

Purpose This review aimed to summarize the treatment outcomes of percutaneous radiofrequency ablation (RFA) and microwave ablation (MWA) for metastatic liver tumors based on the findings of published studies over the last decade. Materials and methods Literature describing the survival outcomes of ablation therapy for liver metastases was explored using the PubMed database on April 26, 2022, and articles published in 2012 or later were selected. The included studies met the following criteria: (i) English literature, (ii) original clinical studies, and (iii) literature describing overall survival (OS) of thermal ablation for metastatic liver tumors. All case reports and cohort studies with fewer than 20 patients and those that evaluated ablation for palliative purposes were excluded. Results RFA was the most commonly used method for ablation, while MWA was used in several recent studies. RFA and MWA for liver metastases from various primary tumors have been reported; however, majority of the studies focused on colorectal cancer. The local control rate by RFA and MWA varied widely among the studies, ranging approximately 50–90%. Five-year survival rates of 20–60% have been reported following ablation for colorectal liver metastases by a number of studies, and several reports of 10-year survival rates were also noted. Conclusion Comparative studies of local therapies for colorectal liver metastases demonstrated that RFA provides comparable survival outcomes to surgical metastasectomy and stereotactic body radiation therapy.

show abstract

Section: Results In Each Type Of Primary Tumormentioning

confidence: 99%

Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade

et al. 2022

View full text Add to dashboard Cite

show abstract

Systemic chemotherapy combined with radiofrequency ablation for colorectal cancer with liver metastasis: a retrospective cohort study

Tran,

Nguyen,

Pham

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Background: This study aims to evaluate the efficacy of systemic chemotherapy combined with radiofrequency ablation in the treatment of inoperable colorectal cancer with liver metastasis. Materials and methods: The authors conducted a retrospective cohort analysis on 30 patients diagnosed as colorectal cancer with liver metastasis who underwent systemic chemotherapy combined with radiofrequency ablation of the liver lesions from January 2017 to August 2020 at our institution. Responses was evaluated by International Working Group on Image-guided Tumor Ablation criteria, along with progression-free survival. Results: The response rate after 4 cycles and 8 cycles of chemotherapy were 73.3% and 85.2%, respectively. All patients achieved responses after of radiofrequency therapy, with the rates of complete response and partial response were 63.3% and 36.7%. The median progression-free survival was 16.7 months. After radiotherapy ablation, all patients had mild to moderate hepatic pain, 10% of patients had fever and increased liver enzymes occurred in 90% of patients. Conclusions: Systemic chemotherapy combined with radiofrequency ablation was safe and effective in colorectal cancer with liver metastasis and warrants further large-scale studies.

show abstract

Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward

Lin

Paolucci

Brock

et al. 2021

Cancers

View full text Add to dashboard Cite

Image-guided ablation can provide effective local tumor control in selected patients with CLM. A randomized controlled trial suggested that radiofrequency ablation combined with systemic chemotherapy resulted in a survival benefit for patients with unresectable CLM, compared to systemic chemotherapy alone. For small tumors, ablation with adequate margins can be considered as an alternative to resection. The improvement of ablation technologies can allow the treatment of tumors close to major vascular structures or bile ducts, on which the applicability of thermal ablation modalities is challenging. Several factors affect the outcomes of ablation, including but not limited to tumor size, number, location, minimal ablation margin, RAS mutation status, prior hepatectomy, and extrahepatic disease. Further understanding of the impact of tumor biology and advanced imaging guidance on overall patient outcomes might help to tailor its application, and improve outcomes of image-guided ablation.

show abstract

Prognostic Factors of Radiofrequency Ablation plus Systemic Chemotherapy for Unresectable Colorectal Cancer with Liver Metastasis

Cited by 3 publications

References 23 publications

Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade

Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade

Systemic chemotherapy combined with radiofrequency ablation for colorectal cancer with liver metastasis: a retrospective cohort study

Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward

Contact Info

Product

Resources

About